Pricing Log in Create free account
Saturday 17 October 2026 Export INDV’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

INDV Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

32.45 1.17 −3.48%
Market cap
$4.0B
P/E
11.2×
Fwd P/E
11.8×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Indivior PLC (INDV) Business Profile

Updated before January 2025

Company Overview

Indivior PLC (INDV) is a global pharmaceutical company specializing in the development, manufacture, and commercialization of medications designed to treat addiction and serious mental health conditions. The company was founded in 2014 as a spin-off from Reckitt Benckiser Group. Headquartered in Richmond, Virginia, USA, Indivior operates globally, with a strong presence in North America, Europe, and other key markets. The company is led by a team of experienced executives, including its CEO, Mark Crossley, who has been instrumental in driving the company’s strategic vision and growth.

Indivior’s mission is to pioneer life-transforming treatments for patients struggling with addiction and mental health disorders. The company has a rich history of innovation in the addiction treatment space, particularly in opioid dependence, and continues to focus on addressing unmet medical needs in this critical area.

Core Business Segments

Indivior operates primarily in the addiction treatment and mental health sectors. Its core business segments include:

1. Addiction Treatment

Indivior is best known for its leadership in opioid dependence treatment. The company’s flagship product, Suboxone® (buprenorphine and naloxone), is a leading medication for opioid dependence. Suboxone is available in both film and tablet formulations, offering flexibility for patients and healthcare providers.

Another key product in this segment is Sublocade®, an extended-release injectable formulation of buprenorphine. Sublocade provides a once-monthly treatment option for patients, improving adherence and reducing the risk of misuse.

2. Mental Health

Indivior has also expanded its portfolio to address serious mental health conditions. The company’s product Perseris® is an extended-release injectable formulation of risperidone, used to treat schizophrenia in adults. This product underscores Indivior’s commitment to providing innovative solutions for mental health challenges.

3. Pipeline Development

Indivior invests heavily in research and development (R&D) to expand its product portfolio. The company is actively working on new formulations and treatments for addiction and mental health disorders, aiming to address unmet medical needs and improve patient outcomes.

Business Model

Indivior’s business model revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products. The company generates revenue primarily through the sale of its branded medications, such as Suboxone, Sublocade, and Perseris. Indivior’s approach integrates:

  • Patient-Centric Solutions: The company focuses on developing treatments that improve patient adherence and outcomes, such as long-acting injectables.
  • Global Reach: Indivior markets its products in multiple countries, leveraging its strong distribution network and partnerships with healthcare providers.
  • R&D Investment: A significant portion of Indivior’s revenue is reinvested into R&D to drive innovation and maintain its leadership in addiction treatment.

Strategic Direction

Indivior’s strategic priorities include:

  • Expanding the Addiction Treatment Portfolio: The company aims to develop new formulations and delivery methods to enhance patient outcomes and address emerging needs in addiction treatment.
  • Growth in Mental Health: Indivior plans to strengthen its presence in the mental health sector by expanding the use of Perseris and developing new treatments for psychiatric disorders.
  • Sustainability Goals: The company is committed to reducing its environmental footprint and promoting sustainable practices across its operations.
  • Geographic Expansion: Indivior seeks to increase its market share in emerging markets, where the demand for addiction and mental health treatments is growing.

Competitive Landscape

Indivior operates in a highly competitive pharmaceutical industry. Key competitors include:

  • Alkermes: A biopharmaceutical company specializing in treatments for central nervous system disorders, including addiction.
  • Camurus: Known for its long-acting injectable treatments for opioid dependence.
  • Teva Pharmaceuticals: A global leader in generic and specialty medicines, including addiction treatments.
  • Generic Manufacturers: Indivior faces competition from generic versions of Suboxone, which have impacted its market share.

Despite the competition, Indivior differentiates itself through its innovative product offerings and strong focus on patient outcomes.

Risk Factors

Indivior faces several risks that could impact its business:

  • Market Dependence: A significant portion of the company’s revenue comes from Suboxone and Sublocade. Any decline in sales of these products could adversely affect the company’s financial performance.
  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and changes in regulations or delays in product approvals could impact Indivior’s operations.
  • Supply Chain Disruptions: The company relies on a global supply chain for the production and distribution of its products. Disruptions in the supply chain could affect product availability.
  • Litigation Risks: Indivior has faced legal challenges related to its marketing practices and intellectual property, which could result in financial penalties or reputational damage.

Recent Developments

Indivior has made significant strides in recent years:

  • Launch of Sublocade: The company has successfully launched Sublocade in multiple markets, positioning it as a leading treatment for opioid dependence.
  • R&D Advancements: Indivior continues to invest in its pipeline, with several promising candidates in various stages of development.
  • Strategic Partnerships: The company has entered into collaborations with healthcare providers and organizations to expand access to its treatments.
  • COVID-19 Impact: The pandemic highlighted the importance of addressing mental health and addiction issues, leading to increased demand for Indivior’s products.

Investment Considerations

Strengths:

  • Market Leadership: Indivior is a leader in the addiction treatment space, with a strong portfolio of innovative products.
  • R&D Focus: The company’s commitment to innovation positions it well for long-term growth.
  • Global Presence: Indivior’s extensive distribution network enables it to reach patients worldwide.

Risks:

  • Revenue Concentration: Dependence on a few key products poses a risk to the company’s financial stability.
  • Regulatory and Legal Challenges: Ongoing litigation and regulatory scrutiny could impact the company’s operations.
  • Competition: The entry of generic competitors could erode market share and pricing power.

Conclusion

Indivior PLC is a leading player in the addiction treatment and mental health sectors, with a strong track record of innovation and patient-centric solutions. While the company faces challenges such as competition and regulatory risks, its strategic focus on R&D, sustainability, and geographic expansion positions it well for future growth. Investors should weigh the company’s strengths and risks carefully when considering it as a potential investment opportunity.